研究单位：[1]Ascentage Pharma Group Inc.[2]Chongqing Cancer Hospital Chongqing, Chongqing, China[3]Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China[4]Guangxi Medical University Affiliated Tumor Hospital Nanning, Guangxi, China[5]The Affiliated Hospital of Guizhou Medical University Guiyang, Guizhou, China[6]The Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China河北医科大学第四医院[7]Henan Provincial Oncology Hospital Zhenzhou, Henan, China[8]Union Hospital medical college Huazhong University of Science and Technology Wuhan, Hubei, China[9]Xiangya Hospital Central South University Changsha, Hunan, China[10]The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, China[11]Zhongda Hospital Southeast University Nanjing, Jiangsu, China[12]The First affiliated hospital of Soochow University Suzhou, Jiangsu, China[13]The First affiliated hospital of Nanchang University Nanchang, Jiangxi, China[14]Fudan University Shanghai Cancer Center Shanghai, Shanghai, China[15]Fudan University Zhongshan Hospital Shanghai, Shanghai, China[16]Blood Diseases Hospital Chinese Academy of Medical Sciences Tianjin, Tianjin, China[17]The First Bethune Hospital of Jilin University Hangzhou, Zhejiang, China[18]The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China[19]Peking University Third Hospital Beijing, Beijing, China
The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.
